← Back to Search

Farnesyltransferase Inhibitor, Statin, Bisphosphonate

Lonafarnib + Zoledronic Acid + Pravastatin for Progeria

Phase 2
Waitlist Available
Led By Mark Kieran, MD, PhD
Research Sponsored by Boston Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical Diagnosis: Patients must display clinical signs of progeria as per the clinical trial team.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a combination of 3 drugs to see if it can improve the symptoms of Progeria, a rare disease that causes premature death.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Patients must show signs of progeria as determined by the clinical trial team.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the therapeutic effects of the combination of zoledronic acid, pravastatin and lonafarnib in patients with HGPS.
Secondary outcome measures
To assay for changes in research-based potential markers of efficacy such as levels of prelamin A, mature lamin A, progerin, and HP1 in protein isolated from PBL.
To assay for the inhibition of HDJ-2 farnesylation in Peripheral Blood Leukocytes (PBL).
To assess changes in auditory function, dental anomalies, dermatologic changes including hair density, nutrition with calorie analysis and energy expenditure, body composition analysis by DXA scan, and cardiovascular structure and function.
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment armExperimental Treatment1 Intervention
All patients will receive zoledronic acid, pravastatin and lonafarnib

Find a Location

Who is running the clinical trial?

Boston Children's HospitalLead Sponsor
756 Previous Clinical Trials
5,579,134 Total Patients Enrolled
2 Trials studying Progeria
85 Patients Enrolled for Progeria
Merck Sharp & Dohme LLCIndustry Sponsor
3,860 Previous Clinical Trials
5,047,769 Total Patients Enrolled
Eiger BioPharmaceuticalsIndustry Sponsor
21 Previous Clinical Trials
7,220 Total Patients Enrolled
1 Trials studying Progeria

Media Library

Lonafarnib, Pravastatin, Zoledronic Acid (Farnesyltransferase Inhibitor, Statin, Bisphosphonate) Clinical Trial Eligibility Overview. Trial Name: NCT00916747 — Phase 2
Progeria Research Study Groups: Treatment arm
Progeria Clinical Trial 2023: Lonafarnib, Pravastatin, Zoledronic Acid Highlights & Side Effects. Trial Name: NCT00916747 — Phase 2
Lonafarnib, Pravastatin, Zoledronic Acid (Farnesyltransferase Inhibitor, Statin, Bisphosphonate) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00916747 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the approved treatments that Lonafarnib, Zoledronic Acid, and Pravastatin are used for?

"Lonafarnib, Zoledronic Acid, and Pravastatin are often employed in the treatment of myocardial revascularization. This medical intervention can also be used to improve cardiovascular disease (cvd), hutchinson-gilford progeria syndrome, and low-density lipoproteins."

Answered by AI

Do these drugs have Food and Drug Administration sanctioning?

"While there is some safety data for this combination therapy, it received a score of 2 because there are no clinical trials demonstrating its efficacy."

Answered by AI

How many people are currently participating in this trial?

"Unfortunately, this study is not presently looking for new patients. The listing was originally posted on August 1st 2009 but was last updated on March 7th 2022. There are other clinical trials underway that may be of interest; including 2 studies recruiting patients with progeria and 55 studies involving Lonafarnib, Zoledronic Acid, and Pravastatin which are actively enrolling patients."

Answered by AI

Are there any vacancies in this clinical trial for new patients?

"This is an inactive clinical trial, as indicated by the date of the most recent edit on clinicaltrials.gov. The last update was on March 7th, 2022 and the trial was originally posted August 1st, 2009. There are 57 other trials that patients can participate in at this time."

Answered by AI
~5 spots leftby Mar 2025